Eurofins CDMO Alphora Inc. (Canada) Announces the Relocation and Expansion of its Analytical Services and Research & Development Laboratories to New Campus Hosting all Biopharmaceutical Activities

MISSISSAUGA, Canada--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc. is pleased to announce the relocation and expansion of its API development laboratories from 2395 Speakman Drive to its new, owned facility at 2070 Hadwen Road, located within the Sheridan Research Park in Mississauga, Ontario, Canada.

This 56,000 square foot building is the new home of Eurofins CDMO Alphora Inc’s API process R&D activity, solid-state R&D activity and its analytical services team. The state-of-the-art laboratory facility includes 26 fume hoods supporting Process R&D; a 50L scale Kilo laboratory equipped with 6 walk-in fume hoods; cGMP Analytical Services; HPAPI development laboratories; a new Bruker 400 mHz NMR; as well as offices for employees and client meetings. The new facility expands capacity to support the continued growth of client programs and offers new Kilo Laboratory services for larger quantities of preclinical materials for toxicological studies.

The 2070 Hadwen site seamlessly fits into Eurofins CDMO Alphora Inc’s vision for its 14-acre campus located over two nearly adjacent sites within the Sheridan Research Park, establishing a suite of complementary and integrated service offerings to support biopharmaceutical development. The new Hadwen API development laboratories are located nearly opposite the corporate site at 2240 Speakman Drive, which also houses drug product development and manufacturing, quality assurance, the newly completed 100L scale GMP HPAPI facility (2022), and a 2000L scale GMP API plant (operational mid-2023). The campus is also within 2.5 km of Eurofins CDMO Alphora Inc.’s existing API production facility.

This latest addition is another important step towards Eurofins CDMO Alphora Inc’s’ vision to build out its Sheridan Research Park campus with additional capacity and technologies in CDMO and biopharmaceutical services.

To learn more, please visit: www.eurofins.com/cdmo

About Eurofins CDMO:
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization that provides clients with active pharmaceutical ingredients (“API’s”) / drug substance and drug product development for small molecules and biologics. Its service offering encompasses drug substance/API development, solid state research and development, pre-formulation, formulation and development, analytical development, GMP manufacturing and clinical packaging and logistics. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.